AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30131296 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 148
Study 30131296 — intervention group
Group type: COMPARATOR
Intervention: Inhaled normal saline (placebo)
Number of subjects: 148
Study 27827358 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) treatment
Number of subjects: 60
Study 27827358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 25450275 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 396
Study 25450275 — intervention group
Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 396
Study 22459648 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 25
Study 22459648 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 20146631 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir 50 mg
Number of subjects: 278
Study 20146631 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir 125 mg
Number of subjects: 278
Study 20146631 — intervention group
Group type: COMPARATOR
Intervention: CPI/r
Number of subjects: 278
Study 17875063 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg
Number of subjects: 90
Study 17875063 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone 25/250 microg
Number of subjects: 90
Study 17875063 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg
Number of subjects: 90
Study 17875063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16158032 — intervention group
Group type: EXPERIMENTAL
Intervention: MIAS
Number of subjects: 72
Study 16158032 — intervention group
Group type: COMPARATOR
Intervention: TPA
Number of subjects: 72
Study 16158032 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA
Number of subjects: 72
Study 12074254 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra-substituted diet (31% metabolizable fat) for 14 days in Study One
Number of subjects: 25
Study 12074254 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra-containing diet (31% metabolizable fat) for 10 weeks in Study Two
Number of subjects: 25
Study 12074254 — intervention group
Group type: COMPARATOR
Intervention: Control diet (40% fat) for 10 weeks in Study Two
Number of subjects: 25
Study 12074254 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat diet (31% fat) for 10 weeks in Study Two
Number of subjects: 25
Study 10086544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin therapy
Number of subjects: 34
Study 10086544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8775646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15
Study 8775646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 15
Study 8775646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2246794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Marital Therapy
Number of subjects: 33
Study 2246794 — intervention group
Group type: COMPARATOR
Intervention: Control group (programmed marital enhancement text)
Number of subjects: 33
Study 7404146 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (Hypnomidate)
Number of subjects: 80
Study 7404146 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 80
Study 31713631 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-CLS pacing algorithm for 12 months
Number of subjects: 54
Study 31713631 — intervention group
Group type: COMPARATOR
Intervention: DDI group (sham DDI mode)
Number of subjects: 54
Study 29127575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy for 30 minutes daily for 28 days
Number of subjects: 81
Study 29127575 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy for 30 minutes daily for 28 days
Number of subjects: 81
Study 28485261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 28485261 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 25442724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates technique
Number of subjects: 125
Study 25442724 — intervention group
Group type: COMPARATOR
Intervention: Vazirani-Akinosi technique
Number of subjects: 125
Study 23711998 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CBI)
Number of subjects: 328
Study 23711998 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-based intervention (TBI)
Number of subjects: 328
Study 23711998 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study 21332628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus statin (EZE/statin)
Number of subjects: 21794
Study 21332628 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 21794
Study 18362594 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.01-0.04 microg x kg x min)
Number of subjects: 10
Study 18362594 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10
Study 18362594 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3.0 mg)
Number of subjects: 10
Study 18362594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18362594 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 17174195 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg NM-702
Number of subjects: 386
Study 17174195 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg NM-702
Number of subjects: 386
Study 17174195 — intervention group
Group type: EXPERIMENTAL
Intervention: NM-702 (both doses)
Number of subjects: 386
Study 17174195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 14702886 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum mood disorder treatments (specific treatments not detailed in the abstract)
Number of subjects: 1000
Study 14702886 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening instruments for postpartum mood disorders (specific instruments not detailed in the abstract)
Number of subjects: 1000
Study 10879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment with prenatal care
Number of subjects: 87
Study 10879333 — intervention group
Group type: COMPARATOR
Intervention: Control group (prenatal care only)
Number of subjects: 87
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I (2EHRZ7/6EH7): 8-month daily regimen of ethambutol, isoniazid, rifampicin, and pyrazinamide for 2 months, followed by ethambutol and isoniazid for 6 months.
Number of subjects: 1203
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II (2EHRZ2/4EHR2): 6-month twice-weekly regimen with the same four drugs for 2 months, followed by ethambutol, rifampicin, and isoniazid for 4 months.
Number of subjects: 1203
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen III (2HRZ2/4HR2): similar to Reg. II, but without ethambutol.
Number of subjects: 1203
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I for isoniazid resistant group (94 patients).
Number of subjects: 1203
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II for isoniazid resistant group (59 patients).
Number of subjects: 1203
Study 9487448 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen III for isoniazid resistant group (74 patients).
Number of subjects: 1203
Study 8238493 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin infusion (3,620 +/‐ 476 pM)
Number of subjects: 9
Study 3552204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of cyclophosphamide
Number of subjects: 7
Study 3552204 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of cyclophosphamide
Number of subjects: 7
Study 30312165 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal decoction (180 mL of Cassia fistula L pod's pericarp and Myristica fragrans Houtt arils)
Number of subjects: 64
Study 30312165 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg orally twice daily)
Number of subjects: 64
Study 30312165 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal decoction
Number of subjects: 64
Study 30312165 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 64
Study 28489253 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen plug procedure
Number of subjects: 94
Study 28489253 — intervention group
Group type: COMPARATOR
Intervention: Mucosal advancement flap surgery
Number of subjects: 94
Study 26123683 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin exposure for 130 minutes
Number of subjects: 50
Study 26123683 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐1,3‐d‐Glucan exposure for 130 minutes
Number of subjects: 50
Study 26123683 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin exposure
Number of subjects: 50
Study 23899667 — intervention group
Group type: EXPERIMENTAL
Intervention: FeS (ferrous sulfate)
Number of subjects: 20
Study 23899667 — intervention group
Group type: COMPARATOR
Intervention: C (controls)
Number of subjects: 20
Study 20924292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional simulation training (1-hour session)
Number of subjects: 37
Study 20924292 — intervention group
Group type: COMPARATOR
Intervention: Standard training on pedicle screw insertion
Number of subjects: 37
Study 18230228 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional disclosure (EMO)
Number of subjects: 63
Study 18230228 — intervention group
Group type: EXPERIMENTAL
Intervention: Best possible self (BPS)
Number of subjects: 63
Study 18230228 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CTL)
Number of subjects: 63
Study 16644785 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 45
Study 16644785 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 45
Study 16644785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12871321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (n = 357; opposed (n = 290) and unopposed (n = 67))
Number of subjects: 719
Study 12871321 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 362)
Number of subjects: 719
Study 10741256 — intervention group
Group type: EXPERIMENTAL
Intervention: Semax administered intransally as nasal drops
Number of subjects: 0
Study 10741256 — intervention group
Group type: EXPERIMENTAL
Intervention: Semax administered by endonasal electrophoresis
Number of subjects: 0
Study 10741256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no semax)
Number of subjects: 0
Study 8781668 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to common airborne allergens
Number of subjects: 2841
Study 8781668 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity
Number of subjects: 2841
Study 1594787 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes with 'rediffusion system'
Number of subjects: 0
Study 1594787 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tubes without 'rediffusion system'
Number of subjects: 0
Study 6384851 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic therapy (tranexamic acid)
Number of subjects: 360
Study 6384851 — intervention group
Group type: COMPARATOR
Intervention: No antifibrinolytic therapy (Control)
Number of subjects: 360
Study 6384851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral cervical sutures
Number of subjects: 360
Study 30981026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual use of e‐cigarettes and cigarettes (11.1% of cigarette users)
Number of subjects: 727
Study 30981026 — intervention group
Group type: COMPARATOR
Intervention: Cigarette-only smokers
Number of subjects: 727
Study 30537714 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 90
Study 30537714 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 90
Study 26980919 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen spray (3 times daily)
Number of subjects: 84
Study 26980919 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (3 times daily)
Number of subjects: 84
Study 24350736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound localization (IUL)
Number of subjects: 107
Study 24350736 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgery
Number of subjects: 107
Study 22902096 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14
Study 22902096 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14
Study 22902096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Simvastatin and Bezafibrate)
Number of subjects: 14
Study 19953579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine plus normal saline (group 1; n = 38)
Number of subjects: 186
Study 19953579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine plus 3% saline (group 2; n = 39)
Number of subjects: 186
Study 19953579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol plus normal saline (group 3; n = 36)
Number of subjects: 186
Study 19953579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol plus 3% saline (group 4; n = 36)
Number of subjects: 186
Study 19953579 — intervention group
Group type: COMPARATOR
Intervention: normal saline alone (group 5; n = 37)
Number of subjects: 186
Study 17683650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 220000
Study 17683650 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 220000
Study 17683650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic bisphosphonate intervention
Number of subjects: 220000
Study 15896289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 30
Study 15896289 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control)
Number of subjects: 30
Study 12585098 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin principle (YQYY)
Number of subjects: 40
Study 12585098 — intervention group
Group type: COMPARATOR
Intervention: Conventional method with corticosteroids and/or immunosuppressant
Number of subjects: 40
Study 10029403 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on infant behaviors, states, and communication cues
Number of subjects: 29
Study 7564842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal constrictor myotomy
Number of subjects: 29
Study 7564842 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pharyngeal plexus neurectomy
Number of subjects: 29
Study 7564842 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pharyngeal plexus neurectomy with drainage myotomy limited to the cricopharyngeus
Number of subjects: 29
Study 1300803 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and preoperative radiotherapy
Number of subjects: 387
Study 1300803 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 387
Study 3895037 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid therapy (up to 1200 mg/d)
Number of subjects: 6
Study 3895037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31362667 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP variants genotyping via Sequenom's MassARRAY® genotyping platform (iPLEX GOLD)
Number of subjects: 130
Study 31362667 — intervention group
Group type: COMPARATOR
Intervention: Comparison of allelic frequencies with 18 other populations
Number of subjects: 130
Study 29610630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprobe biopsy (CB)
Number of subjects: 92
Study 29610630 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible forceps biopsy (FFB)
Number of subjects: 92
Study 29610630 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed pleural biopsy (CPB)
Number of subjects: 92
Study 29610630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological cell block (CCB)
Number of subjects: 92
Study 27038406 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Number of subjects: 60
Study 27038406 — intervention group
Group type: COMPARATOR
Intervention: No-Braun anastomosis
Number of subjects: 60
Study 23512235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-space injection of Twin mix
Number of subjects: 60
Study 23512235 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone
Number of subjects: 60
Study 23512235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 60
Study 23512235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 60
Study 23512235 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-oral dexamethasone
Number of subjects: 60
Study 23512235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 60
Study 21827450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0
Study 21827450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19858140 — intervention group
Group type: EXPERIMENTAL
Intervention: L-FMC after isometric exercise
Number of subjects: 112
Study 19858140 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD after isometric exercise
Number of subjects: 112
Study 19858140 — intervention group
Group type: COMPARATOR
Intervention: Combination of L-FMC and FMD
Number of subjects: 112
Study 17645472 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN 1.0 mug/kg/week + ribavirin 10.6 mg/kg/day
Number of subjects: 103
Study 17645472 — intervention group
Group type: COMPARATOR
Intervention: peg‐IFN 1.5 microg/kg/week + ribavirin 10.6 mg/kg/day
Number of subjects: 103
Study 15980699 — intervention group
Group type: COMPARATOR
Intervention: VaxGen VAX004 study (HIV vaccine efficacy trial)
Number of subjects: 5417
Study 12021683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care
Number of subjects: 0
Study 12021683 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 9419453 — intervention group
Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P2 (group 5)
Number of subjects: 51
Study 9419453 — intervention group
Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 (group 4)
Number of subjects: 51
Study 9419453 — intervention group
Group type: COMPARATOR
Intervention: Peptides alone (PSM-P1 or PSM-P2; group 1 and 2)
Number of subjects: 51
Study 9419453 — intervention group
Group type: COMPARATOR
Intervention: Autologous DC (group 3)
Number of subjects: 51
Study 9419453 — intervention group
Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 or PSM-P2 (group 4 and 5)
Number of subjects: 51
Study 8089248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 20
Study 8089248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cetylpyridinium chloride (CPC)
Number of subjects: 20
Study 8089248 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20
Study 8089248 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 20
Study 8089248 — intervention group
Group type: COMPARATOR
Intervention: Control rinse (minus active)
Number of subjects: 20
Study 2841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20-40 mg)
Number of subjects: 69
Study 2841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg)
Number of subjects: 69
Study 31661606 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum CA19‐9 levels
Number of subjects: 27009
Study 31661606 — intervention group
Group type: COMPARATOR
Intervention: Weighted genetic risk score for CA19‐9
Number of subjects: 27009
Study 29016835 — intervention group
Group type: EXPERIMENTAL
Intervention: MVS with epicardial left atrial cryoablation
Number of subjects: 65
Study 29016835 — intervention group
Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 65
Study 29016835 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sinus rhythm
Number of subjects: 65
Study 29016835 — intervention group
Group type: COMPARATOR
Intervention: Patients with AF
Number of subjects: 65
Study 28494795 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care
Number of subjects: 128
Study 28494795 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (enhanced standard of care + group-based intervention)
Number of subjects: 128
Study 28494795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (averaging over study condition)
Number of subjects: 128
Study 26044206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 36
Study 26044206 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 36
Study 23642946 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90
Study 23642946 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 90
Study 23642946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clay surface
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpet surface
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Forehand stroke on clay
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Backhand stroke on clay
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Forehand stroke on carpet
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Backhand stroke on carpet
Number of subjects: 10
Study 21088546 — intervention group
Group type: EXPERIMENTAL
Intervention: Same stroke at different velocities
Number of subjects: 10